Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes

Atherosclerosis

Volumn 219, Issue 1, 2011, Pages 342-348

  Vergès, Bruno ^a   Duvillard, Laurence ^a   Brindisi, Marie Claude ^a   Gautier, Emmanuel ^b   Krempf, Michel ^b,c   Costet, Philippe ^b   Cariou, Bertrand ^b,c  

^a HÔPITAL DU BOCAGE   (France)

^b L INSTITUT DU THORAX   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

Apolipoprotein B; Diabetes; LDL catabolism; Lipoprotein kinetics; PCSK9

Indexed keywords

APOLIPOPROTEIN B; CARBON 13; LEUCINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; PROPROTEIN CONVERTASE 1; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SULFONYLUREA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CATABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIET RESTRICTION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRACTIONAL CATABOLIC RATE; GAS CHROMATOGRAPHY; HUMAN; ISOTOPE LABELING; ISOTOPE RATIO MASS SPECTROMETRY; LIPOPROTEIN METABOLISM; MALE; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ADULT; AGED; APOLIPOPROTEIN B-100; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 80055018021     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.07.098     Document Type: Article

References (45)

1. Costet P., Krempf M., Cariou B. PCSK9 and LDL cholesterol: unravelling the target to design the bullet. Trends Biochem Sci 2008, 33:426-434.
2. Dubuc G., Chamberland A., Wassef H., et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004, 24:1454-1459.
3. Rashid S., Curtis D.E., Garuti R., et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA 2005, 102:5374-5379.
4. Konrad R.J., Troutt J.S., Cao G. Effects of currently prescribed LDL-C lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis 2011, 10:38.
5. Cariou B., Le May C., Costet P. Clinical aspects of PCSK9. Atherosclerosis 2011, 216:258-265.
6. Lakoski S.G., Lagace T.A., Cohen J.C., Horton J.D., Hobbs H.H. Plasma levels of PCSK9 in a large multiethnic population. J Clin Endocrinol Metab 2009, 94:2537-2543.
7. Baass A., Dubuc G., Tremblay M., et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009, 55:1637-1645.
8. Welder G., Zineh I., Pacanowski M.A., Troutt J.S., Cao G., Konrad R.J. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010, 51:2714-2721.
9. Chan D.C., Lambert G., Barrett P.H., Rye K.A., Ooi E.M., Watts G.F. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism?. Clin Chem 2009, 55:2049-2052.
10. Cariou B., Ouguerram K., Zair Y., et al. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 2009, 29:2191-2197.
11. Dubuc G., Tremblay M., Paré G., et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res 2010, 51:140-149.
12. Ouguerram K., Chetiveaux M., Zair Y., et al. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol 2004, 24:1448-1453.
13. Costet P., Cariou B., Lambert G., et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem 2006, 281:6211-6218.
14. Niesen M., Bedi M., Lopez D. Diabetes alters LDL receptor and PCSK9 expression in rat liver. Arch Biochem Biophys 2008, 470:111-115.
15. Mbikay M., Sirois F., Mayne J., et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett 2010, 584:701-706.
16. Langhi C., Le May C., Gmyr V., et al. PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. Biochem Biophys Res Commun 2009, 390:1288-1293.
17. Kappelle P.J., Lambert G., Dullaart R.P. Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients. Atherosclerosis 2011, 214:432-435.
18. Vergès B. Lipid modification in type 2 diabetes: the role of LDL and HDL. Fundam Clin Pharmacol 2009, 23:681-685.
19. Duvillard L., Pont F., Florentin E., Gambert P., Vergès B. Significant improvement of apolipoprotein B-containing lipoprotein metabolism by insulin treatment in patients with non-insulin-dependent diabetes mellitus. Diabetologia 2000, 43:27-35.
20. Taskinen M.R., Packard C.J., Shepherd J. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes 1990, 39:1017-1027.
21. Pont F., Duvillard L., Maugeais C., et al. Isotope ratio mass spectrometry, compared with conventional mass spectrometry in kinetic studies at low and high enrichment levels: application to lipoprotein kinetics. Anal Biochem 1997, 248:277-287.
22. Cohn J.S., McNamara J.R., Cohn S.D., Ordovas J.M., Schaefer E.J. Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal. J Lipid Res 1988, 29:925-936.
23. Vergès B., Rader D., Schaefer J., et al. In vivo metabolism of apolipoprotein A-IV in severe hypertriglyceridemia: a combined radiotracer and stable isotope kinetic study. J Lipid Res 1994, 35:2280-2291.
24. Cobelli C., Toffolo G., Foster D.M. Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism. Am J Physiol 1992, 262:E968-E975.
25. Millar J.S., Maugeais C., Ikewaki K., et al. Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production. Arterioscler Thromb Vasc Biol 2005, 25:560-565.
26. Barrett P.H.R., Bell B.M., Cobelli C., et al. Simulation analysis and modeling software for tracer and pharmacokinetic studies. Metabolism 1998, 47:484-492.
27. Pont F., Duvillard L., Vergès B., Gambert P. Development of compartmental models in stable isotope experiments: application to lipid metabolism. Arterioscler Thromb Vasc Biol 1998, 18:853-860.
28. Foster D.M., Aamodt R.L., Henkin R.I., Berman M. Zinc metabolism in humans: a kinetic model. Am J Physiol 1979, 237:R340-R349.
29. Parhofer K.G., Hugh P., Barrett R., Bier D.M., Schonfeld G. Determination of kinetic parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes. J Lipid Res 1991, 32:1311-1323.
30. Millar J.S., Lichtenstein A.H., Cuchel M., et al. Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men. J Lipid Res 1995, 36:1155-1167.
31. Cummings M.H., Watts G.F., Pal C., et al. Increased hepatic secretion of very low density lipoprotein apolipoprotein B100 in obesity: a stable isotope study. Clin Sci 1995, 88:225-233.
32. Pont F., Duvillard L., Florentin E., Gambert P., Vergès B. High density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study. Int J Obes Relat Metab Disord 2002, 26:1151-1158.
33. Dagher F.J., Lyons J.H., Finlayson D.C., Shamsai J., Moore F.D. Blood volume measurement: a critical study. Adv Surg 1965, 1:69-109.
34. Grefhorst A., Mc Nutt M.C., Lagace T.A., Horton J.D. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res 2008, 49:1303-1311.
35. Brouwers M.C.G.J., Troutt J.S., van Greevenbroek M.M.J., et al. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: the CODAM study. Atherosclerosis 2010, doi:10.1016/j.atherosclerosis.2011.03.023.
36. Yamamoto T., Lu C., Ryan R.O. A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor. J Biol Chem 2011, 286:5464-5470.
37. Witzum J.L., Mahoney E.M., Bronks M.J., et al. Non enzymatic glucosylation of low density lipoprotein alters its biologic activity. Diabetes 1982, 31:283-291.
38. Wade D.P., Knight B.L., Soutar A.K. Regulation of low-density-lipoprotein-receptor mRNA by insulin in human hepatoma HepG2 cells. Eur J Biochem 1989, 181:727-731.
39. Polonsky K.S., Sturis J., Bell G.I. Seminars in Medicine of the Beth Israel Hospital Boston. Non-insulin-dependent diabetes mellitus-a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996, 334:777-783.
40. Cohn J.S., Wagner D.A., Cohn S.D., Millar J.S., Schaefer E.J. Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J Clin Invest 1990, 85:804-811.
41. Demant T., Packard C.J., Demmelmair H., et al. Sensitive methods to study human apolipoprotein B metabolism using stable isotope-labeled amino acids. Am J Physiol 1996, 270:E1022-E1036.
42. Barrett P.H., Chan D.C., Watts G.F. Thematic review series: patient-oriented research. Design and analysis of lipoprotein tracer kinetics studies in humans. J Lipid Res 2006, 47:1607-1619.
43. 3C] leucine. Am J Physiol 1980, 238:E473-E479.
44. Mazière J.C., Mazière C., Mora L., et al. The antidiabetic drug metformin decreases cholesterol metabolism in cultured human fibroblasts. Atherosclerosis 1988, 71:27-33.
45. Wulffelé M.G., Kooy A., de Zeeuw D., Stehouwer C.D., Gansevoort R.T. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 2004, 256:1-14.